Patiromer

How it works

Benefits

Evidence quality

Highlighted claims

• Patiromer is a non-absorbed cation-exchange polymer that binds potassium in the gastrointestinal tract. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Adding patiromer to standard combination therapy did not produce statistically significant efficacy over placebo for urgent hyperkalaemia in the emergency department. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Patiromer has demonstrated efficacy and safety in outpatient populations with chronic kidney disease, diabetes, and heart failure. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Patiromer plus standard therapy was associated with fewer total adverse events than placebo plus standard therapy, although the proportion of patients experiencing at least one adverse event did not differ significantly. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Because patiromer is not systemically absorbed, a ventricular tachycardia event in a patiromer patient was considered more likely attributable to hyperkalaemia itself. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Real-world emergency department observational studies have not consistently shown significant benefit for patiromer compared with insulin or sodium zirconium cyclosilicate. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department